Weedmaps S4 Update: Unlicensed Risks, CBD Upside, New Model

by | Jan 27, 2021 | Company Analysis

Our investment thesis on Weedmaps is that it is a growth adtech firm providing investors with exposure to increasing US cannabis sales without trafficking in cannabis itself.

At 14X 2021 sales and 56X 2021 EBITDA, the stock performance going forward will come down to progress towards hitting the company’s targets of $440 million in revenue and $130 million in EBITDA in 2023.